Scinai Immunotherapeutics Ltd. has announced a remarkable 167% increase in revenue for the first nine months of 2026, a significant achievement for the biopharmaceutical company. This growth is attributed to the expansion of its contract development and manufacturing organization (CDMO) business, particularly following the acquisition of new operations earlier this year. The increase not only highlights Scinai's operational success but also reflects a broader positive trend within the biological products sector.

In a press release dated November 5, 2026, Scinai reported that its revenue surged to $2.8 million, up from $1.05 million during the same period last year. The company attributed this growth to its CDMO operations, which have gained traction since acquiring Yavne operations in February 2026.

Background

Scinai Immunotherapeutics Ltd. operates within the biopharmaceutical industry, specifically categorized under the SIC code 2836, which focuses on biological products excluding diagnostic substances. The company trades on the Nasdaq under the ticker SCNI and is classified as a non-accelerated filer. Its recent filings include several reports, with the latest being a 6-K filed on November 9, 2026.

What the Filing Says

The filing reveals that Scinai's revenue growth is primarily driven by an expanded U.S. customer agreement for its CDMO subsidiary, Scinai Biopharma Services Ltd. The agreement, which includes approximately $5.1 million in committed base service fees, underscores the company's strategic focus on enhancing its customer relationships and operational capabilities.

Amir Reichman, the CEO of Scinai, commented on the results, stating, "Our nine-month revenue of $2.8 million shows the growing contribution of the CDMO business, including the Yavne operations we acquired earlier this year." The report also highlighted that committed customer orders reached approximately $8.32 million as of November 4, 2026, compared to $1.9 million at the end of 2025, marking an increase of over 330%.

Impact

This significant revenue growth may positively affect various stakeholders, including investors, employees, and customers. Investors may see this as a sign of the company's strengthening financial position, while employees may benefit from increased job security and growth opportunities. Customers could experience enhanced service offerings as the company expands its operational capabilities.

What's Next

Looking ahead, Scinai is focused on converting its commitments into revenue and improving cash flow. The company plans to continue leveraging its CDMO capabilities to meet customer milestones while controlling delivery costs. The filing does not specify what happens next, but the ongoing expansion of customer programs and operational efficiencies is expected to play a crucial role in Scinai's future growth.